- ICH GCP
- Реестр клинических исследований ЕС
Последние исследования
EudraCT Number: 2020-000976-40 | Sponsor Protocol Number: ION373-CS1 | Start Date: | |||||||||||
Sponsor Name: Ionis Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand... | |||||||||||||
Medical condition: Alexander Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017477-38 | Sponsor Protocol Number: MEK112110 | Start Date: | |||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Evero... | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009320-36 | Sponsor Protocol Number: 28431754DIA3009 | Start Date: | |||||||||||
Sponsor Name: Janssen Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared Wit... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DE (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015125-36 | Sponsor Protocol Number: NCT00934687 | Start Date: | ||||||
Sponsor Name: Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy | ||||||||
Full Title: Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie | ||||||||
Medical condition: Botulinum Toxin for the Treatment of Depression | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000846-38 | Sponsor Protocol Number: R076477-BIM-3004 | Start Date: | |||||||||||
Sponsor Name: Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an ... | |||||||||||||
Medical condition: Bipolar I disorder, most recent maniac or mixed episode | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005168-15 | Sponsor Protocol Number: CQAV680A2201 | Start Date: | |||||||||||
Sponsor Name: Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placeb... | |||||||||||||
Medical condition: Mild to moderate persistent asthma, steroid-free patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000127-14 | Sponsor Protocol Number: NCT-2017-0516 | Start Date: | ||||||
Sponsor Name: Heidelberg University Hospital | ||||||||
Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies | ||||||||
Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN... | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: SE (Ongoing) DE (Ongoing) NL (Ongoing) FR (Ongoing) AT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004942-14 | Sponsor Protocol Number: IJB-LOB-2019 | Start Date: | |||||||||||
Sponsor Name: Institut Jules Bordet | |||||||||||||
Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast | |||||||||||||
Medical condition: ER-positive/HER2-negative invasive lobular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004016-58 | Sponsor Protocol Number: WPD-201P | Start Date: | ||||||
Sponsor Name: WPD Pharmaceuticals Sp. z o.o. | ||||||||
Full Title: A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin® in Pediatric Patients with Progressive, Refractory, or Recurrent Hig... | ||||||||
Medical condition: High Grade Gliomas | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: PL (Prematurely Ended) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001516-30 | Sponsor Protocol Number: GDX-44-007 | Start Date: | ||||||||||||||||
Sponsor Name: GUERBET | ||||||||||||||||||
Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI. | ||||||||||||||||||
Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Ongoing) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |